Kindeva Drug Delivery: acquisition of iPharma Labs

CDMO Kindeva Drug Delivery has completed its acquisition of iPharma Labs, a company based in the Bay Area of San Francisco. The purchase brings together iPharma’s expertise and capabilities in inhalation formulation and development of liquid, dry powder, and propellant-based therapies with Kindeva’s expertise in developing, commercializing, and manufacturing inhaled therapies.

Keith Ung, CEO and cofounder of iPharma, noted, “Joining Kindeva strengthens our ability to craft the best product development strategy for delivery to the patient to and through the lungs. Our customers are already excited to benefit from a more complete product development and manufacturing offering. I am pleased to continue to lead the team here in Union City as the site head and R&D director and look forward to leading efforts at Kindeva to expand our clinical and commercial support for dry powder and nebulized respiratory therapies​.”